Literature DB >> 26730158

Correlational research of Golgi phosphorylation protein 3 expression in colorectal cancer.

Yan-Ta Guo1, Cheng-Zhi Qiu1, Zhong-Xin Huang1, Wai-Shi Yu1, Xiao-Feng Yang1, Ming-Zhen Wang1.   

Abstract

AIM: To investigate the effect of Golgi phosphorylation protein 3 (GOLPH3) expression on cell apoptosis, angiogenesis and prognosis in colorectal cancer (CRC).
METHODS: The expression of GOLPH3 in CRC tissues and normal colorectal mucosae was determined by immunohistochemistry in 62 patients. In addition, immunohistochemistry was also carried out to detect the expression of vascular endothelial growth factor (VEGF), CD34 and microvessel density (MVD). Terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling assay was used to determine the apoptotic index (AI). The Kaplan-Meier method was used to analyze the relationship between GOLPH3 expression and survival in another 123 CRC cases.
RESULTS: Compared with normal colorectal mucosae, a notably higher level of GOLPH3 protein expression was identified in CRC tissues (53.2% vs 24.2%, P < 0.05). Positive GOLPH3 expression was significantly associated with tumor invasion depth, TNM stage, and lymph node metastasis (P = 0.001; P = 0.020; P = 0.020; P < 0.05, respectively), but not with tumor length, tumor site, and age (P = 0.363; P = 0.819; P = 0.599; P > 0.05, respectively). VEGF expression and MVD in GOLPH3-positive CRC was significantly higher than in GOLPH3-negative CRC (VEGF: 69.7% vs 31.0%; MVD: 21.45 ± 9.39 vs 14.24 ± 8.97; P < 0.05). GOLPH3 expression was negatively correlated with AI in CRC as shown by Spearman correlation analysis (r = -0.320, P < 0.05). The 5-year survival rate in GOLPH3-negative CRC (69.4%) was significantly higher than in GOLPH3-positive CRC (48.6%) (log-rank test, P < 0.05).
CONCLUSION: High expression of GOLPH3 is found in CRC tissues. GOLPH3 expression may be a novel prognostic marker for CRC patients.

Entities:  

Keywords:  Angiogenesis; Cell apoptosis; Colorectal cancer; Golgi phosphorylation protein 3; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26730158      PMCID: PMC4690176          DOI: 10.3748/wjg.v21.i48.13473

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

Review 1.  GOLPH3 links the Golgi, DNA damage, and cancer.

Authors:  Matthew D Buschman; Juliati Rahajeng; Seth J Field
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

2.  Blocking effects of siRNA on VEGF expression in human colorectal cancer cells.

Authors:  Yu Yin; Li-Yu Cao; Wen-Qing Wu; Hao Li; Yan Jiang; Hong-Fu Zhang
Journal:  World J Gastroenterol       Date:  2010-03-07       Impact factor: 5.742

3.  Direct involvement of phosphatidylinositol 4-phosphate in secretion in the yeast Saccharomyces cerevisiae.

Authors:  H Hama; E A Schnieders; J Thorner; J Y Takemoto; D B DeWald
Journal:  J Biol Chem       Date:  1999-11-26       Impact factor: 5.157

Review 4.  Colorectal cancer.

Authors:  David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321

5.  Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor.

Authors:  Zhaolei Zeng; Huanxin Lin; Xiaohui Zhao; Guanglin Liu; Xi Wang; Ruihua Xu; Kun Chen; Jun Li; Libing Song
Journal:  Clin Cancer Res       Date:  2012-06-06       Impact factor: 12.531

6.  Phosphatidylinositol 4 phosphate regulates targeting of clathrin adaptor AP-1 complexes to the Golgi.

Authors:  Ying Jie Wang; Jing Wang; Hui Qiao Sun; Manuel Martinez; Yu Xiao Sun; Eric Macia; Tomas Kirchhausen; Joseph P Albanesi; Michael G Roth; Helen L Yin
Journal:  Cell       Date:  2003-08-08       Impact factor: 41.582

7.  High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis.

Authors:  Jian-Hua Wang; Xiu-Ting Chen; Zhe-Sheng Wen; Min Zheng; Jian-Ming Deng; Ming-Zhi Wang; Huan-Xin Lin; Kun Chen; Jun Li; Jing-Ping Yun; Rong-Zhen Luo; Li-Bing Song
Journal:  PLoS One       Date:  2012-10-02       Impact factor: 3.240

Review 8.  Clinical application of genetics in management of colorectal cancer.

Authors:  Eun Ran Kim; Young-Ho Kim
Journal:  Intest Res       Date:  2014-07-25

9.  GOLPH3L antagonizes GOLPH3 to determine Golgi morphology.

Authors:  Michelle M Ng; Holly C Dippold; Matthew D Buschman; Christopher J Noakes; Seth J Field
Journal:  Mol Biol Cell       Date:  2013-01-23       Impact factor: 4.138

10.  Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.

Authors:  Xing Hua; Lina Yu; Wenhai Pan; Xiaoxiao Huang; Zexiao Liao; Qi Xian; Li Fang; Hong Shen
Journal:  Diagn Pathol       Date:  2012-09-24       Impact factor: 2.644

View more
  13 in total

Review 1.  GOLPH3: a Golgi phosphatidylinositol(4)phosphate effector that directs vesicle trafficking and drives cancer.

Authors:  Ramya S Kuna; Seth J Field
Journal:  J Lipid Res       Date:  2018-09-28       Impact factor: 5.922

2.  Golgi-Related Proteins GOLPH2 (GP73/GOLM1) and GOLPH3 (GOPP1/MIDAS) in Cutaneous Melanoma: Patterns of Expression and Prognostic Significance.

Authors:  Piotr Donizy; Maciej Kaczorowski; Przemyslaw Biecek; Agnieszka Halon; Teresa Szkudlarek; Rafal Matkowski
Journal:  Int J Mol Sci       Date:  2016-10-01       Impact factor: 5.923

3.  GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer.

Authors:  Kunli Zhu; Qianqian Zhao; Jinbo Yue; Pengyue Shi; Hongjiang Yan; Xiaoqing Xu; Renben Wang
Journal:  Oncotarget       Date:  2016-10-18

4.  The knocking down of the oncoprotein Golgi phosphoprotein 3 in T98G cells of glioblastoma multiforme disrupts cell migration by affecting focal adhesion dynamics in a focal adhesion kinase-dependent manner.

Authors:  Cecilia Arriagada; Charlotte Luchsinger; Alexis E González; Tomás Schwenke; Gloria Arriagada; Hugo Folch; Pamela Ehrenfeld; Patricia V Burgos; Gonzalo A Mardones
Journal:  PLoS One       Date:  2019-02-19       Impact factor: 3.240

5.  Golgi phosphoprotein 3 sensitizes the tumour suppression effect of gefitinib on gliomas.

Authors:  Xu Wang; Zhaohao Wang; Yu Zhang; Yan Wang; Hao Zhang; Shao Xie; Peng Xie; Rutong Yu; Xiuping Zhou
Journal:  Cell Prolif       Date:  2019-05-16       Impact factor: 6.831

6.  Tenacissoside H Induces Apoptosis and Inhibits Migration of Colon Cancer Cells by Downregulating Expression of GOLPH3 Gene.

Authors:  Zhong-Shi Hong; Hai-Bin Zhuang; Cheng-Zhi Qiu; Ze-Sheng Shi; Chun-Xiao Wang; Zhi-Chuan Chen; Jian-Peng Pan
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-07       Impact factor: 2.629

Review 7.  Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer.

Authors:  Stefano Sechi; Anna Frappaolo; Angela Karimpour-Ghahnavieh; Roberto Piergentili; Maria Grazia Giansanti
Journal:  Int J Mol Sci       Date:  2020-01-31       Impact factor: 5.923

8.  Golgi Phosphoprotein 3 Represents a Novel Tumor Marker for Gastric and Colorectal Cancers.

Authors:  Chun-Xiao Wang; Hai-Bin Zhuang; Ze-Sheng Shi; Cheng-Zhi Qiu; Zhi-Xiong Chen; Long-Feng Tang
Journal:  Dis Markers       Date:  2021-02-23       Impact factor: 3.434

9.  Clinicopathologic and prognostic implications of Golgi Phosphoprotein 3 in colorectal cancer: A meta-analysis.

Authors:  Tao Wang; Jiandong Fei; Shuangfa Nie
Journal:  PLoS One       Date:  2021-11-22       Impact factor: 3.240

Review 10.  Myosin Motors: Novel Regulators and Therapeutic Targets in Colorectal Cancer.

Authors:  Nayden G Naydenov; Susana Lechuga; Emina H Huang; Andrei I Ivanov
Journal:  Cancers (Basel)       Date:  2021-02-11       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.